Symbols / MBOT
MBOT Chart
About
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 170.58M |
| Enterprise Value | 91.32M | Income | -13.07M | Sales | — |
| Book/sh | 1.19 | Cash/sh | 1.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | — | Forward P/E | -7.26 | PEG | — |
| P/S | — | P/B | 2.14 | P/C | — |
| EV/EBITDA | -6.54 | EV/Sales | — | Quick Ratio | 27.32 |
| Current Ratio | 27.53 | Debt/Eq | 1.15 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 16:00 | ROA | -20.17% |
| ROE | -31.87% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 67.16M |
| Shs Float | 67.16M | Short Float | 9.05% | Short Ratio | 5.29 |
| Short Interest | — | 52W High | 4.67 | 52W Low | 1.25 |
| Beta | 1.29 | Avg Volume | 2.24M | Volume | 7.77M |
| Target Price | $7.50 | Recom | Strong_buy | Prev Close | $2.05 |
| Price | $2.54 | Change | 23.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.50
Mean price target
2. Current target
$2.54
Latest analyst target
3. DCF / Fair value
$-1.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.54
Low
$5.00
High
$12.00
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | init | B. Riley Securities | — → Buy | $5 |
| 2025-12-03 | init | Roth Capital | — → Buy | $6 |
| 2025-11-28 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-10-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-11 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-04-16 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-10-18 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-06-06 | reit | HC Wainwright & Co. | — → Buy | $8 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2020-08-18 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2020-01-13 | reit | HC Wainwright & Co. | — → Buy | $26 |
| 2019-12-24 | reit | HC Wainwright & Co. | — → Buy | $12 |
| 2019-07-22 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2018-11-19 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2018-01-31 | init | Ladenburg Thalmann | — → Buy | $2 |
- Tampa General turns to single-use vascular surgery robot LIBERTY - Stock Titan ue, 24 Feb 2026 13
- $2.12 Pre Market 18 Feb 2026: MBOT Microbot Medical Inc NASDAQ – 91% upside - Meyka Wed, 18 Feb 2026 11
- Microbot Medical Announces Material Definitive Agreement Disclosure - TipRanks Wed, 25 Feb 2026 01
- Tampa General Hospital Adopts Small-Cap Microbot Medical's Robotic System - Benzinga ue, 24 Feb 2026 18
- Microbot Medical: High-Risk High-Return Stock, Still Hard To Value (NASDAQ:MBOT) - Seeking Alpha hu, 22 Jan 2026 08
- Microbot Medical adjusts executive compensation and awards special CEO bonus - Investing.com ue, 24 Feb 2026 22
- Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones - GlobeNewswire Mon, 12 Jan 2026 08
- Here's Why We're Not Too Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation - Yahoo Finance Sun, 07 Dec 2025 08
- Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT) - Nasdaq Wed, 29 Oct 2025 07
- MBOT - Microbot Med Inc Latest Stock News & Market Updates - Stock Titan ue, 07 Oct 2025 07
- Microbot Medical®’s LIBERTY® Endovascular Robotic System - GlobeNewswire hu, 19 Feb 2026 13
- Limited Q4 2025 LIBERTY release — Microbot Medical secures U.S. logistics partner ahead of April 2026 launch - Stock Titan ue, 14 Oct 2025 07
- Microbot Medical (NASDAQ: MBOT) starts limited release of LIBERTY; full launch April 2026 - Stock Titan Wed, 05 Nov 2025 08
- Microbot Medical (Nasdaq: MBOT) adds Emory as first LIBERTY endovascular robotics site - Stock Titan Wed, 26 Nov 2025 08
- $92.2M Potential Funding: Microbot Medical Announces Major Investment Options Exercise for LIBERTY Robot - Stock Titan Mon, 15 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.53M | -9.20M | -13.55M | -11.32M |
| TotalUnusualItems | 0.00 | -832.00K | 215.00K | 44.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -832.00K | 215.00K | 44.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.44M | -10.74M | -13.17M | -11.31M |
| ReconciledDepreciation | 91.00K | 106.00K | 102.00K | 76.00K |
| EBITDA | -11.53M | -10.03M | -13.34M | -11.28M |
| EBIT | -11.62M | -10.14M | -13.44M | -11.36M |
| NetInterestIncome | 182.00K | 228.00K | 54.00K | 44.00K |
| InterestIncome | 283.00K | 54.00K | ||
| NormalizedIncome | -11.44M | -9.91M | -13.38M | -11.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.44M | -10.74M | -13.17M | -11.31M |
| TotalExpenses | 11.62M | 10.14M | 13.44M | 11.36M |
| TotalOperatingIncomeAsReported | -11.62M | -9.86M | -13.28M | -11.36M |
| DilutedAverageShares | 15.64M | 10.20M | 7.26M | 7.11M |
| BasicAverageShares | 15.64M | 10.20M | 7.26M | 7.11M |
| DilutedEPS | -0.73 | -1.05 | -1.81 | -1.59 |
| BasicEPS | -0.73 | -1.05 | -1.81 | -1.59 |
| DilutedNIAvailtoComStockholders | -11.44M | -10.74M | -13.17M | -11.31M |
| NetIncomeCommonStockholders | -11.44M | -10.74M | -13.17M | -11.31M |
| NetIncome | -11.44M | -10.74M | -13.17M | -11.31M |
| NetIncomeIncludingNoncontrollingInterests | -11.44M | -10.74M | -13.17M | -11.31M |
| NetIncomeContinuousOperations | -11.44M | -10.74M | -13.17M | -11.31M |
| PretaxIncome | -11.44M | -10.74M | -13.17M | -11.31M |
| OtherIncomeExpense | -832.00K | 215.00K | 44.00K | |
| SpecialIncomeCharges | 0.00 | -832.00K | 151.00K | 131.00K |
| GainOnSaleOfPPE | 0.00 | -2.00K | -5.00K | 0.00 |
| OtherSpecialCharges | 830.00K | -156.00K | ||
| RestructuringAndMergernAcquisition | -131.00K | |||
| GainOnSaleOfSecurity | -55.00K | 64.00K | -87.00K | |
| NetNonOperatingInterestIncomeExpense | 182.00K | 228.00K | 54.00K | 44.00K |
| TotalOtherFinanceCost | -182.00K | -228.00K | -44.00K | |
| InterestIncomeNonOperating | 283.00K | 54.00K | ||
| OperatingIncome | -11.62M | -10.14M | -13.44M | -11.36M |
| OperatingExpense | 11.62M | 10.14M | 13.44M | 11.36M |
| OtherOperatingExpenses | 74.00K | 95.00K | 120.00K | 108.00K |
| DepreciationAmortizationDepletionIncomeStatement | 4.00K | |||
| DepreciationAndAmortizationInIncomeStatement | 4.00K | |||
| DepreciationIncomeStatement | 4.00K | |||
| ResearchAndDevelopment | 6.63M | 5.72M | 7.74M | 6.15M |
| SellingGeneralAndAdministration | 4.92M | 4.32M | 5.58M | 5.10M |
| GeneralAndAdministrativeExpense | 4.92M | 4.32M | 5.58M | 5.10M |
| OtherGandA | 1.43M | 1.66M | 1.67M | 1.77M |
| InsuranceAndClaims | 442.00K | 442.00K | 733.00K | 732.00K |
| SalariesAndWages | 3.05M | 2.21M | 3.18M | 2.59M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 19.40M | 11.71M | 7.89M | 7.11M |
| ShareIssued | 19.40M | 11.71M | 7.89M | 7.11M |
| TotalDebt | 111.00K | 231.00K | 462.00K | 680.00K |
| TangibleBookValue | 3.53M | 4.50M | 7.29M | 14.38M |
| InvestedCapital | 3.53M | 4.50M | 7.29M | 14.38M |
| WorkingCapital | 3.36M | 4.13M | 6.75M | 13.89M |
| NetTangibleAssets | 3.53M | 4.50M | 7.29M | 14.38M |
| CapitalLeaseObligations | 111.00K | 231.00K | 462.00K | 680.00K |
| CommonStockEquity | 3.53M | 4.50M | 7.29M | 14.38M |
| TotalCapitalization | 3.53M | 4.50M | 7.29M | 14.38M |
| TotalEquityGrossMinorityInterest | 3.53M | 4.50M | 7.29M | 14.38M |
| StockholdersEquity | 3.53M | 4.50M | 7.29M | 14.38M |
| RetainedEarnings | -90.94M | -79.50M | -68.76M | -55.59M |
| AdditionalPaidInCapital | 94.28M | 83.88M | 75.97M | 69.90M |
| CapitalStock | 195.00K | 118.00K | 80.00K | 72.00K |
| CommonStock | 195.00K | 118.00K | 80.00K | 72.00K |
| TotalLiabilitiesNetMinorityInterest | 2.50M | 3.83M | 2.25M | 2.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 41.00K | 40.00K | 179.00K | 402.00K |
| LongTermDebtAndCapitalLeaseObligation | 41.00K | 40.00K | 179.00K | 402.00K |
| LongTermCapitalLeaseObligation | 41.00K | 40.00K | 179.00K | 402.00K |
| CurrentLiabilities | 2.46M | 3.79M | 2.07M | 1.98M |
| OtherCurrentLiabilities | 5.00K | 79.00K | 298.00K | 396.00K |
| CurrentDebtAndCapitalLeaseObligation | 70.00K | 191.00K | 283.00K | 278.00K |
| CurrentCapitalLeaseObligation | 70.00K | 191.00K | 283.00K | 278.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.41M | 725.00K | 1.37M | 1.03M |
| PayablesAndAccruedExpenses | 976.00K | 2.79M | 116.00K | 279.00K |
| CurrentAccruedExpenses | 811.00K | 2.43M | 0.00 | |
| Payables | 165.00K | 357.00K | 116.00K | 279.00K |
| AccountsPayable | 165.00K | 357.00K | 116.00K | 279.00K |
| TotalAssets | 6.03M | 8.33M | 9.54M | 16.77M |
| TotalNonCurrentAssets | 212.00K | 406.00K | 723.00K | 888.00K |
| NetPPE | 212.00K | 406.00K | 723.00K | 888.00K |
| AccumulatedDepreciation | -584.00K | -493.00K | -387.00K | -289.00K |
| GrossPPE | 796.00K | 899.00K | 1.11M | 1.18M |
| Leases | 229.00K | 229.00K | 229.00K | 229.00K |
| OtherProperties | 502.00K | 644.00K | ||
| MachineryFurnitureEquipment | 435.00K | 410.00K | 379.00K | 304.00K |
| BuildingsAndImprovements | 132.00K | 260.00K | 502.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.82M | 7.92M | 8.81M | 15.88M |
| RestrictedCash | 49.00K | 49.00K | 77.00K | 87.00K |
| PrepaidAssets | 429.00K | 126.00K | ||
| Receivables | 300.00K | 1.49M | 532.00K | 174.00K |
| OtherReceivables | 300.00K | 1.49M | 532.00K | 174.00K |
| LoansReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 5.47M | 6.38M | 8.21M | 15.49M |
| OtherShortTermInvestments | 2.36M | 3.92M | 5.76M | 2.00M |
| CashAndCashEquivalents | 3.11M | 2.47M | 2.44M | 13.49M |
| CashEquivalents | 0.00 | 1.25M | 0.00 | |
| CashFinancial | 3.11M | 2.47M | 1.20M | 13.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.85M | -8.57M | -11.63M | -9.42M |
| IssuanceOfCapitalStock | 7.94M | 6.56M | 4.32M | 0.00 |
| CapitalExpenditure | -25.00K | -33.00K | -84.00K | -69.00K |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 3.16M | 2.52M | 2.52M | 13.58M |
| BeginningCashPosition | 2.52M | 2.52M | 13.58M | 19.73M |
| ChangesInCash | 646.00K | -2.00K | -11.06M | -6.15M |
| FinancingCashFlow | 7.94M | 6.56M | 4.32M | 0.00 |
| CashFlowFromContinuingFinancingActivities | 7.94M | 6.56M | 4.32M | 0.00 |
| NetCommonStockIssuance | 7.94M | 6.56M | 4.32M | 0.00 |
| CommonStockIssuance | 7.94M | 6.56M | 4.32M | 0.00 |
| InvestingCashFlow | 1.54M | 1.97M | -3.84M | 3.20M |
| CashFlowFromContinuingInvestingActivities | 1.54M | 1.97M | -3.84M | 3.20M |
| NetInvestmentPurchaseAndSale | 1.56M | 2.01M | -3.75M | 3.27M |
| SaleOfInvestment | 6.68M | 12.07M | 0.00 | 3.27M |
| PurchaseOfInvestment | -5.12M | -10.06M | -3.75M | 0.00 |
| NetPPEPurchaseAndSale | -25.00K | -33.00K | -84.00K | -69.00K |
| PurchaseOfPPE | -25.00K | -33.00K | -84.00K | -69.00K |
| OperatingCashFlow | -8.83M | -8.53M | -11.55M | -9.35M |
| CashFlowFromContinuingOperatingActivities | -8.83M | -8.53M | -11.55M | -9.35M |
| ChangeInWorkingCapital | 942.00K | -11.00K | -228.00K | 497.00K |
| ChangeInPayablesAndAccruedExpense | 873.00K | -683.00K | -241.00K | 320.00K |
| ChangeInPrepaidAssets | 69.00K | 672.00K | 13.00K | 177.00K |
| OtherNonCashItems | 234.00K | 716.00K | -12.00K | |
| StockBasedCompensation | 1.35M | 1.39M | 1.75M | 1.39M |
| UnrealizedGainLossOnInvestmentSecurities | -12.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 91.00K | 106.00K | 102.00K | 76.00K |
| DepreciationAndAmortization | 91.00K | 106.00K | 102.00K | 76.00K |
| Depreciation | 91.00K | 106.00K | 102.00K | |
| OperatingGainsLosses | 2.00K | 5.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 5.00K | 0.00 |
| NetIncomeFromContinuingOperations | -11.44M | -10.74M | -13.17M | -11.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MBOT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|